Contact Us
E-mail: nihresearchmatters@od.nih.gov
Mailing Address:
NIH Research Matters
Bldg. 31, Rm. 5B64A, MSC 2094
Bethesda, MD 20892-2094
NIH Research Matters
Bldg. 31, Rm. 5B64A, MSC 2094
Bethesda, MD 20892-2094
About NIH Research Matters
Editor: Harrison Wein, Ph.D.
Assistant Editors: Vicki Contie, Carol Torgan, Ph.D.
Assistant Editors: Vicki Contie, Carol Torgan, Ph.D.
NIH Research Matters is a weekly update of NIH research highlights from the Office of Communications and Public Liaison, Office of the Director, National Institutes of Health.
ISSN 2375-9593
Boosting Immunotherapy Against Brain Cancer
Cancer immunotherapies harness the potential of the immune system to seek and destroy cancers. They first came into use in the 1990s, and the field is now quickly advancing. One innovative approach being developed is to use dendritic cells. These are a type of immune cell that captures microorganisms and processes their proteins to present to other immune cells and prompt a response.
An artist’s representation of the surface of a human dendritic cell. Image courtesy of NCI.
Dendritic cells have recently been used for immunotherapy to target a variety of tumor types. Dendritic cells are isolated from the patient’s blood, engineered to express antigens from the tumor, and then injected back into the patient as a vaccine. Once in the patient, the engineered dendritic cells migrate to the lymph node and activate T cells to fight the tumor and create an immune memory to prevent the cancer from coming back.
Researchers led by Drs. Duane A. Mitchell and John H. Sampson at Duke University Medical Center tested whether a strategy to increase dendritic cell migration to lymph nodes would improve the effects of a dendritic cell vaccine against glioblastoma multiforme, the most common form of malignant brain cancer in adults. The vaccine targeted an antigen from cytomegalovirus. The role of this virus in disease progression is unclear, but past studies have found that cytomegalovirus proteins are specifically expressed in glioblastoma tumors but not in normal brain cells.
Twelve patients newly diagnosed with glioblastoma were given standard radiation and chemotherapy, and randomly divided into 2 groups. One group received a tetanus booster shot, designed to set off an inflammatory response at the site of the vaccination and prep the immune system. The other patients were injected with their own unaltered dendritic cells instead of a tetanus shot. All were then treated with the dendritic cell vaccine against the cytomegaloviral antigen. The research was funded in part by NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI).
The results, published on March 19, 2015, in Nature, showed that administering a tetanus booster before the vaccine increased dendritic cell migration to lymph nodes and significantly improved both the time without disease progression and overall survival. Patients who received the tetanus booster lived an average of more than 3 years after diagnosis compared to 1.5 years in those who received dendritic cells alone.
The team used a mouse model to determine how the tetanus booster increased dendritic cell migration to lymph nodes. They found that migration depended on memory T cells specific to the tetanus toxoid. Migration also depended on 2 signaling proteins known to guide cell migration: chemokines CCL3 and CCL21.
“We did not expect that enhancing dendritic cell migration would be associated with such a dramatic improvement on clinical outcomes in our patients,” Mitchell says.
Larger clinical studies will be needed to confirm this approach of boosting immune responses and targeting cytomegalovirus in glioblastomas. Continued research into the mechanisms involved in the response to cancer vaccines—and how best to target cytomegalovirus and other tumor proteins—may also lead to further improvements.
RELATED LINKS:
- Technique Visualizes Brain Tumors During Surgery:
http://www.nih.gov/researchmatters/september2013/09162013tumors.htm - Neighbors Help Cancer Cells Resist Treatment:
http://www.nih.gov/researchmatters/july2012/07232012cancer.htm - Subtypes of Deadly Brain Cancer Identified:
http://www.nih.gov/researchmatters/february2010/02012010braincancer.htm - Adult Brain Tumors Treatment:
http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/Patient - Immunotherapy: Using the Immune System to Treat Cancer:
http://www.cancer.gov/researchandfunding/areas/treatment/immunotherapy-using-immune-system
Reference: Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Nature. 2015 Mar 19;519(7543):366-9. doi: 10.1038/nature14320. Epub 2015 Mar 11. PMID: 25762141.
Funding: NIH’s National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), and National Center for Research Resources (NCRR); the National Brain Tumor Society; the American Brain Tumor Association; Accelerate Brain Cancer Cure Foundation Young Investigator’s Award; The Kinetics Foundation; and Ben and Catherine Ivy Foundation.
.png)
No hay comentarios:
Publicar un comentario